Skip to content

Effects of adjunctive Acetazolamide therapy in patients of Obstructive Sleep Apnea

Randomized Controlled Trial Comparing Standard Treatment of Obstructive Sleep Apnea to Add-On Acetazolamide Treatment - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/054889
Enrollment
60
Registered
2023-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G473- Sleep apnea

Interventions

Intervention1: Positive Airway Pressure: In this arm patients of Obstructive Sleep Apnea patients will be prescribed Positive Airway Pressure in form of CPAP or BIPAP therapy for 4 weeks Control Inter

Sponsors

Anurag Ambikaprasad Tripathi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of Obstructive Sleep Apnea with AHI of 5 and more with no active infections in 4 weeks prior to recruitment with Body Mass Index of at least 20 kg/m2 and Epsworth Sleepiness Score of at least 6.

Exclusion criteria

Exclusion criteria: Refusal to participate Refusal of PAP therapy Allergy to sulfonamides Central sleep apnoea syndromes, dominant Cheyne-Stokes respiration, or significant sleep disorders including periodic limb movements or parasomnia Patients who had received OSA treatment within 4 weeks of the baseline visit Unstable pulmonary or gastrointestinal disease, Severe congestive heart failure, a history of life-threatening arrhythmias, severe cardiomyopathy Significant chronic kidney disease or hepatic disease Potassium levels less than 3 mmol/L Sodium levels less than 125 mEq/L History of mental illness or those on Amphetamines Drug or alcohol abuse, use of sedatives, severe cognitive impairment or Concurrent oncological diseases. Seizure disorders Prior to the treatment with AZM it will be confirmed that no obvious causes of upper airways obstruction have been detected in the nose, throat or lower jaw by examinations performed at the Department of Otorhinolaryngology.

Design outcomes

Primary

MeasureTime frame
Reduction in Apnea Hypopnea Index with Positive airway Pressure and add on AcetazolamideTimepoint: 4 weeks

Secondary

MeasureTime frame
Changes in Pittsburgh Sleep Quality Index with add on Acetazolamide Changes in arterial blood pH, HCO-, and gases with add on Acetazolamide Changes in the sleep parameters with add on Acetazolamide Side effect profile of Acetazolamide Timepoint: 4 weeks

Countries

India

Contacts

Public ContactAnurag Ambikaprasad Tripathi

King Georges Medical University

drvedprakash.07@gmail.com9415091497

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026